Navigation Links
Doctors Would Have 18% of High-Cholesterol Patients take New PCSK9 Inhibitor Drugs Today If FDA Approves Their Use, According to New Data from InCrowd
Date:6/12/2015

BOSTON, June 12, 2015 /PRNewswire/ -- A new survey completed within hours after the US Food & Drug Administration (FDA) hearings this week on two new PCSK9 inhibitors for reducing LDL cholesterol – the first new class of cholesterol-reducing drugs in decades – shows that doctors already are considering prescribing the drug to 18% of their patients, with many regarding the drug class as a "triumph of modern genetic engineering" – while also mindful of the drugs' cost, injectable-only delivery and lack of outcomes studies until 2017.

Data compiled by InCrowd, provider of real-time market intelligence to life sciences firms, represent the first analysis to quantify the expected shift in prescribing patterns represented by the new drug class.

If drugs such as Praluent™ (Sanofi-Regeneron) and Repatha™ (Amgen), which use injected monoclonal antibodies that inhibit the PCSK9 gene, achieve FDA clearance and became available on the market, the cardiologists and primary care physicians (PCPs) surveyed would immediately prescribe them to 7% of their patients as a replacement for their present medications, and to 11% of their patients as an addition to their therapeutic regimen. PCP sentiment was tallied because they represent the front line of cholesterol reduction and prescribe over half of drugs for treating high cholesterol. Survey respondents treated an average of 155 patients per month with high cholesterol in their practices.

Cardiologists were especially enthusiastic, with 76% saying they were very excited about the promise of PCSK9 inhibitors and on average planned to prescribe them for 10% of their patient base as a solo treatment and to 16% of their patients in addition to patients existing drug therapy. Most patients that the doctors would move to the new PCSK9 inhibitors are presently on statins such as Lipitor® (40%), Zocor® (24%) and Crestor® (23%). In a further sign of receptivity, 44% of cardiologists agreed that that would begin prescribing PCSK9 inhibitors as soon as they were approved, compared with 8% of PCPs.  In addition, 80% of cardiologists agreed that the clinical data to date has been shown to be impressively efficacious, compared with 32% of PCPs. 

"This is groundbreaking therapy – a real game-changer," said one doctor, while others said it would "revolutionize treatment for familial hypercholesterolemia" and give options to the statin-intolerant.

Patient cost was the #1 expected barrier to prescribing the drugs and was cited by 79% of respondents, with numerous comments on its "extreme pricing" similar to the early days of statins. Injection dosing was also a concern - "I cannot get the patients to take a pill, let alone an injectable for a condition that does not hurt them," one respondent said - although markedly less to cardiologists (24%) than PCPs (68%).  Interestingly the side effects and safety profile of the new drug category was not a significant issue for most doctors – in fact 20% of cardiologists cited side effects and safety as either a very low concern or no concern at all.

Regardless of FDA recommendations that Praluent and Repatha be used for harder to treat hetereozygous and homozygous familial hypercholesterolemia – results largely reiterated survey results on the types of conditions for which the physicians would prescribe PCSK9 inhibitors  -only 34% of all doctors surveyed believe PCSK9 inhibitors should be restricted to high-risk patients. Some 47% agreed that the PCSK9 inhibitors will satisfy previously unmet major needs in treating high cholesterol.

The survey included 113 physicians – 50 cardiologists and 63 PCPs – who are part of InCrowd's 1.8 million member "Crowd" of verified health care professionals.  Respondents answered the microsurvey during a several-hour time window Wednesday June 10, the majority of which were completed on physicians' mobile devices.  InCrowd's "Crowd" includes a host of other physician clinical specialties groups, nurses, hospital execs, and related life sciences experts. 

Although InCrowd assists 18 of the top 20 pharmas in the world plus other life science firms, InCrowd performed the survey as an independent assessment of prescriber sentiment and not at the request of any interested party.

"We're delighted to help quantify what the medical community thinks about this exciting new class of drugs, and the changes it may bring to the pharmaceutical industry," said Diane Hayes, co-founder and president of InCrowd.

About InCrowd 
InCrowd provides real-time market intelligence from validated experts, connecting life sciences companies directly with prescribers, patients, and other screened and validated healthcare professionals around the globe. Our easy-to-use proprietary web-based application allows clients to ask questions of specific respondent groups – "Crowds" – in the form of 2-5 minute online microsurveys. Responses are available in real time through a password-protected account, with the needed answers delivered within hours or days, not weeks and months.

Today, InCrowd has 18 of the top 20 pharmaceutical firms as customers and has just finished its most successful quarter in company history with a record number of answers delivered to clients. Through its powerful mobile microsurvey methodology and analytics engine, InCrowd enables clients to reach 1.8M healthcare professionals on-demand throughout the United States and around the globe in 20 languages. For more information, visit www.incrowdnow.com.

InCrowd Media Contacts 
Steven Handy
Director of Marketing
steven.handy@incrowdnow.com 
508.944.0787

Mary Kae Marinac 
PR Representative for InCrowd
mkm@mkmarinac.com 
978-685-3136

 


'/>"/>
SOURCE InCrowd
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. International Academy of Low Vision Specialists Announces Training of Doctors in Six New States and Canada
2. Survey Results Show Few Doctors Are Very Confident Managing Patients on Opioids
3. California Medical Board Votes Unanimously To Support A Bill Requiring Doctors Check A Patients Prescription History Before Prescribing Powerful, Addictive Medications, Says Consumer Watchdog
4. Minna Life Survey: 57% of US Women Dont Get Pelvic Floor Information From Doctors
5. New Medical Research Shows Brain Imaging Can Now Help Doctors Differentiate Between PTSD and Traumatic Brain Injuries
6. Diaton Tonometers Unique Transpalpebral Tonometry Capabilities Revealed at ASCRS ASOA Congress in San Diego to 1000s of Eye Doctors
7. Cancer screening rates improve, disparities shrink for patients with Blue Cross Blue Shield of Michigan patient-centered medical home doctors
8. 90% of NJ Residents Want More Information From Their Doctors About Potential Addictive Qualities of the Medications They Are Being Prescribed
9. Consumer Watchdog Calls for Release of Documents on Psychotropic Medication Prescribing in Foster Care, Ban on Big Pharma Payments to Doctors
10. Riordan Clinic IVC Academy Teaches Doctors About the Use of High Dose Vitamin C.
11. Biomet to Pay Over $6 Million to Resolve Whistleblower Claims That It Paid Kickbacks to Doctors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/4/2017)... Korea , Oct. 4, 2017  South Korean-based ... next-generation CPR training aide "cprCUBE" on Kickstarter. The device ... compression during cardiac arrests with better efficiency compared to ... also offers real-time feedback on efficacy of the compression ... crowdfunding campaign has a goal to raise $5,000. ...
(Date:10/2/2017)... , Oct. 2, 2017  Eli Lilly and Company ... results for the third quarter of 2017 on Tuesday, ... call on that day with the investment community and ... The conference call will begin at 9 a.m. ... access a live webcast of the conference call through ...
(Date:9/28/2017)... , Sept. 28, 2017 Hill-Rom Holdings, Inc. ... earnings conference call and webcast on Friday, November 3, ... (EDT) and ending at approximately 8:30 a.m. (CDT) / ... the company,s 2017 financial performance and guidance for 2018, ... initiatives to enhance operational performance, and long-range financial outlook ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... The American ... to become its next President and Chief Executive Officer, succeeding Dr. James C. Puffer ... Elect beginning July 1, 2018 until Dr. Puffer’s retirement at the end of 2018. ...
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a leading Health ... technology. Applying the Purzorb™process to full spectrum CBD oil will revolutionize the rapidly growing ... form that can be easily incorporated into liquid products, while reducing costs to end ...
(Date:10/13/2017)... ... , ... Lori R. Somekh, founder of the Law Office of Somekh ... law and special needs planning attorneys. “Membership in ElderCounsel helps our office remain up ... network with elder law attorneys nationwide,” said Somekh. , ElderCounsel was ...
(Date:10/13/2017)... ... 2017 , ... Many families have long-term insurance that covers care for a ... waiver for care if the client has a cognitive impairment diagnosis. , “What ... is often waived, so the benefits from their insurance start immediately,” said Mechell Vieira, ...
(Date:10/13/2017)... NY (PRWEB) , ... October 13, 2017 , ... Ellevate ... people in business to advocate for action towards gender equality at their inaugural Summit ... from around the globe, and reached a social audience of over 3 million. To ...
Breaking Medicine News(10 mins):